Sensus Healthcare to Participate in the 36th Annual Roth Conference
14 Marzo 2024 - 9:05PM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical
device company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for oncological
and non-oncological conditions, announces management will
participate in one-on-one or small group meetings with
institutional investors at the 36th Annual Roth conference to be
held March 17th – 19th in Dana Point, Calif.
During the meetings, management will discuss its
new Fair Deal Agreement program, which provides an additional
economic value proposition to customers and a recurring revenue
model for Sensus. Management will also discuss the reception it
received at its booth at the American Academy of Dermatology Annual
Meeting earlier this month, as described in its recently issued
press release here.
Investor participation in the conference is by
invitation only. For more information or to request a meeting,
please contact a Roth sales representative. To submit a
registration request, visit
https://ibn.fm/Roth2024Registration.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in
the development and delivery of non-invasive treatments for skin
cancer and keloids. Leveraging its cutting-edge superficial
radiotherapy (SRT and IG-SRT) technology, the company provides
healthcare providers with a highly effective, patient-centric
treatment platform. With a dedication to driving innovation in
radiation oncology, Sensus Healthcare offers solutions that are
safe, precise, and adaptable to a variety of clinical settings. For
more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases,
these statements can be identified by the use of forward-looking
terminology such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," “approximately,” "potential" or negative or other
variations of those terms or comparable terminology, although not
all forward-looking statements contain these words.
Forward-looking statements involve risks and
uncertainties because they relate to events, developments, and
circumstances relating to Sensus, our industry, and/or general
economic or other conditions that may or may not occur in the
future or may occur on longer or shorter timelines or to a greater
or lesser degree than anticipated. Although we believe that we have
a reasonable basis for each forward-looking statement contained in
this press release, forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of
the following factors, among others: our ability to return to
profitability; our ability to sell the number of SRT units we
anticipate for the balance of 2024; the possibility that
inflationary pressures continue to impact our sales; the level and
availability of government and/or third party payor reimbursement
for clinical procedures using our products, and the willingness of
healthcare providers to purchase our products if the level of
reimbursement declines; the regulatory requirements applicable to
us and our competitors; our ability to efficiently manage our
manufacturing processes and costs; the risks arising from doing
business in China and other foreign countries; legislation,
regulation, or other governmental action that affects our products,
taxes, international trade regulation, or other aspects of our
business; concentration of our customers in the U.S. and China,
including the concentration of sales to one particular customer in
the U.S.; our ability to obtain and maintain the intellectual
property needed to adequately protect our products, and our ability
to avoid infringing or otherwise violating the intellectual
property rights of third parties; and other risks described from
time to time in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q.
In addition, even if future events,
developments, and circumstances are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release, except as may
be required by applicable law. You should read carefully our
"Introductory Note Regarding Forward-Looking Information" and the
factors described in the "Risk Factors" section of our periodic
reports filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Contact: LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Grafico Azioni Sensus Healthcare (NASDAQ:SRTS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Sensus Healthcare (NASDAQ:SRTS)
Storico
Da Gen 2024 a Gen 2025